During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Ali Bazarbachi, American University of Beirut Medical Center, Beirut, LB, about allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Why do we see improved survival after allo-HSCT for young patients with AML?
Why do we see improved survival after allo-HSCT for young patients with AML?
Currently, the most important cause of treatment failure is disease relapse after allo-HSCT. The prognosis for these patients has been very poor, however, recent changes in management have started to have an impact. Using data from the EBMT registry of more than 8,000 patients, Ali Bazarbachi's team asked what the influences of year of relapse and relapse characteristics were on outcomes after allo-HSCT.
Following on from this analysis, we asked, Why do we see improved survival after allo-HSCT for young patients with AML?
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox